Author: Gardin, Chiara; Ferroni, Letizia; Chachques, Juan Carlos; Zavan, Barbara
Title: Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients? Cord-id: v2sb90rc Document date: 2020_8_26
ID: v2sb90rc
Snippet: Coronavirus disease 2019 (COVID-19) is a pandemic viral disease originated in Wuhan, China, in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severe form of the disease is often associated with acute respiratory distress syndrome (ARDS), and most critically ill patients require mechanical ventilation and support in intensive care units. A significant portion of COVID-19 patients also develop complications of the cardiovascular system, primarily acu
Document: Coronavirus disease 2019 (COVID-19) is a pandemic viral disease originated in Wuhan, China, in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severe form of the disease is often associated with acute respiratory distress syndrome (ARDS), and most critically ill patients require mechanical ventilation and support in intensive care units. A significant portion of COVID-19 patients also develop complications of the cardiovascular system, primarily acute myocardial injury, arrhythmia, or heart failure. To date, no specific antiviral therapy is available for patients with SARS-CoV-2 infection. Exosomes derived from mesenchymal stem cells (MSCs) are being explored for the management of a number of diseases that currently have limited or no therapeutic options, thanks to their anti-inflammatory, immunomodulatory, and pro-angiogenic properties. Here, we briefly introduce the pathogenesis of SARS-CoV-2 and its implications in the heart and lungs. Next, we describe some of the most significant clinical evidence of the successful use of MSC-derived exosomes in animal models of lung and heart injuries, which might strengthen our hypothesis in terms of their utility for also treating critically ill COVID-19 patients.
Search related documents:
Co phrase search for related documents- acei arb therapy and acute myocardial injury: 1
- aceis arbs and acute ards respiratory distress syndrome: 1, 2, 3
- aceis arbs and acute myocardial infarction: 1
- aceis arbs and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- aceis arbs and acute respiratory distress syndrome ards: 1, 2, 3
- acute ali lung injury and adaptive immune response: 1, 2
- acute ali lung injury and adaptive innate: 1, 2, 3
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and adenine dinucleotide: 1, 2, 3
- acute inflammatory response and adaptive immune response: 1, 2, 3, 4
- acute inflammatory response and adaptive innate: 1, 2, 3, 4, 5, 6
- acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
- acute phase and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute phase and adaptive innate immunity: 1, 2, 3
- acute phase and adenine dinucleotide: 1, 2
- acute respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory distress syndrome and adenine dinucleotide: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date